Summary:
A randomized double blind double dummy placebo controlled dose multi centered study of the efficacy and safety pharma pharmacokinetics and pharma pharmacodynamics of cbp-01 in patient moderate to severe atopic dermatitis.
Qualified Participants Must:
• Must be 18 to 75 years of age
• Must be willing to comply with visits
• At least 1 year of with a topic dermatitis
Qualified Participants May Receive:
$50 per visit for time and travel